Day One Biopharma Files 8-K

Ticker: DAWN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1845337

Sentiment: neutral

Topics: corporate-filing, administrative

Related Tickers: DAWN

TL;DR

Day One Biopharma (DAWN) filed an 8-K confirming its HQ and Nasdaq listing.

AI Summary

On January 13, 2025, Day One Biopharmaceuticals, Inc. filed a Form 8-K to report its current status. The filing confirms the company's principal executive offices are located at 1800 Sierra Point Parkway, Suite 200, Brisbane, California, 94005. Day One Biopharmaceuticals' common stock trades on the Nasdaq Global Select Market under the ticker symbol DAWN.

Why It Matters

This filing serves as a standard update for investors, confirming the company's operational details and stock exchange listing.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report current information as required by the Securities and Exchange Commission, specifically confirming the company's principal executive offices and stock exchange listing.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 13, 2025.

Where are Day One Biopharmaceuticals, Inc.'s principal executive offices located?

Day One Biopharmaceuticals, Inc.'s principal executive offices are located at 1800 Sierra Point Parkway, Suite 200, Brisbane, California, 94005.

On which stock exchange is Day One Biopharmaceuticals, Inc. common stock traded?

Day One Biopharmaceuticals, Inc. common stock is traded on the Nasdaq Global Select Market.

What is the trading symbol for Day One Biopharmaceuticals, Inc. common stock?

The trading symbol for Day One Biopharmaceuticals, Inc. common stock is DAWN.

Filing Stats: 1,095 words · 4 min read · ~4 pages · Grade level 11.2 · Accepted 2025-01-13 08:07:19

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 13, 2025 99.2 J.P. Morgan Healthcare Conference Presentation 99.3 Corporate Presentation 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the Company's preliminary net product revenue results and cash, cash equivalents and short-term investments, as well as the timing and success of the Company's planned nonclinical and clinical development activities, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on October 30, 2024, and the Company's other filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing